{"filing":{"accession_number":"0001193125-26-262264","cik":"0001880438","ticker":"ANTX","company_name":"AN2 Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"antx-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/antx-20260603.htm"},"events":[{"id":6233,"run_id":5469,"accession_number":"0001193125-26-262264","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from AN2 Therapeutics' June 3, 2026 annual meeting, reporting the certified voting outcomes for two proposals: (1) election of three Class I directors (Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.) and (2) ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly matches Item 5.07 requirements and provides detailed vote tallies including votes for/against, withheld votes, and broker non-votes. Director elections are material governance events affecting board composition.","company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5357,"accession_number":"0001193125-26-262264","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from AN2 Therapeutics' June 3, 2026 annual meeting, reporting the certified voting outcomes for two proposals: (1) election of three Class I directors (Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.) and (2) ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly matches Item 5.07 requirements and provides detailed vote tallies including votes for/against, withheld votes, and broker non-votes. Director elections are material governance events affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T10:01:25.287392+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5357,"accession_number":"0001193125-26-262264","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from AN2 Therapeutics' June 3, 2026 annual meeting, reporting the certified voting outcomes for two proposals: (1) election of three Class I directors (Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.) and (2) ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly matches Item 5.07 requirements and provides detailed vote tallies including votes for/against, withheld votes, and broker non-votes. Director elections are material governance events affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T10:01:25.287392+00:00","company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","filing_date":"2026-06-08"}]}